Covalent PAD4 Inhibitors via Electrophilic Warhead Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PAD4 inhibitors lack selectivity for PAD4 over PAD2 and have limited therapeutic applications for PAD4-mediated disorders, such as rheumatoid arthritis, vasculitis, and cancer, due to their non-specific inhibition of peptidylarginine deiminase enzymes.
Innovation Solution
Development of specific compounds, such as those of formula I, which demonstrate selectivity for PAD4 and are used in pharmaceutically acceptable compositions to treat various disorders associated with PAD4, including rheumatoid arthritis, vasculitis, and cancer, by inhibiting PAD4 activity effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PAD4 inhibitors are used, then PAD4 activity is inhibited, but selectivity for PAD4 over PAD2 is poor
Solution Approach 1:
The patent applies local quality by introducing a specific electrophilic warhead group (such as alpha-ketoamide, alpha-hydroxy ketone, or alpha-fluoro ketone) at a defined position in the inhibitor molecule. This localized functional group provides covalent bonding capability that confers both potency and selectivity for PAD4, while the rest of the molecule maintains binding affinity. The warhead group's electrophilic character enables irreversible covalent modification of the catalytic cysteine residue in PAD4, achieving reliable inhibition with improved selectivity over PAD2.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the inhibitor to include specific electrophilic functional groups with defined reactivity parameters. The warhead group's electrophilicity parameter (quantified by pKa or reaction rate constants) is optimized to ensure selective covalent bonding to PAD4's catalytic cysteine while avoiding reaction with PAD2. This parameter optimization achieves both effective inhibition and selective targeting.
2Adaptability or versatility
If non-specific PAD inhibitors are used, then broad enzyme inhibition is achieved, but therapeutic applications for PAD4-mediated disorders are limited
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating the specific functional requirements for PAD4 selectivity. The inhibitor design separates the binding recognition elements (which provide affinity for the PAD family) from the selectivity-determining elements (the electrophilic warhead group that specifically reacts with PAD4's catalytic cysteine). This extraction of the selective covalent bonding mechanism enables therapeutic applications for PAD4-mediated disorders while maintaining controlled enzyme inhibition.
Solution Approach 2:
The electrophilic warhead group acts as an intermediary that mediates selective covalent bonding between the inhibitor and PAD4's catalytic cysteine residue. This intermediary functional group enables the transition from non-specific reversible inhibition to specific irreversible inhibition, providing both therapeutic efficacy for PAD4-mediated disorders and controlled selectivity. The warhead group's intermediate reactivity allows selective modification of PAD4 while sparing PAD2.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds selectively inhibit PAD4, providing therapeutic benefits for PAD4-mediated disorders by reducing inflammation and pathological neutrophil activity, thereby offering improved treatment options for conditions like rheumatoid arthritis and cancer.
Implementation Method 1
The compounds of formula I or a pharmaceutically acceptable salt thereof may be useful as covalent inhibitors of PAD4
Data Source
AI summary
The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.